David E. Kaplan

7.8k total citations · 2 hit papers
194 papers, 4.8k citations indexed

About

David E. Kaplan is a scholar working on Hepatology, Epidemiology and Surgery. According to data from OpenAlex, David E. Kaplan has authored 194 papers receiving a total of 4.8k indexed citations (citations by other indexed papers that have themselves been cited), including 139 papers in Hepatology, 106 papers in Epidemiology and 41 papers in Surgery. Recurrent topics in David E. Kaplan's work include Liver Disease Diagnosis and Treatment (96 papers), Liver Disease and Transplantation (70 papers) and Hepatitis C virus research (47 papers). David E. Kaplan is often cited by papers focused on Liver Disease Diagnosis and Treatment (96 papers), Liver Disease and Transplantation (70 papers) and Hepatitis C virus research (47 papers). David E. Kaplan collaborates with scholars based in United States, United Kingdom and Canada. David E. Kaplan's co-authors include Tamar H. Taddei, David S. Goldberg, Marina Serper, Nadim Mahmud, Kyong‐Mi Chang, Ayse Aytaman, Rajni Mehta, Binu V. John, Shria Kumar and David C. Metz and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

David E. Kaplan

185 papers receiving 4.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores

2019 233 citations George N. Ioannou, Lauren A. Beste et al. Gastroenterology profile →
AASLD Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis

2023 126 citations David E. Kaplan et al. Hepatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David E. Kaplan United States	37	3.0k	2.6k	973	654	497	194	4.8k
Jidong Jia China	40	4.2k 1.4×	4.3k 1.7×	802 0.8×	355 0.5×	426 0.9×	315	6.4k
Jane Collier United Kingdom	32	2.2k 0.8×	2.4k 0.9×	930 1.0×	212 0.3×	531 1.1×	91	4.3k
Josh Levitsky United States	46	3.0k 1.0×	2.6k 1.0×	2.3k 2.4×	374 0.6×	343 0.7×	184	5.7k
S. Fagiuoli Italy	40	3.6k 1.2×	3.1k 1.2×	1.3k 1.3×	162 0.2×	474 1.0×	231	5.7k
Wai‐Kay Seto Hong Kong	49	5.8k 2.0×	6.5k 2.5×	588 0.6×	309 0.5×	455 0.9×	264	7.8k
Pierluigi Toniutto Italy	35	2.7k 0.9×	2.6k 1.0×	938 1.0×	159 0.2×	400 0.8×	179	4.2k
Peter Buggisch Germany	29	3.4k 1.1×	3.3k 1.3×	278 0.3×	446 0.7×	640 1.3×	192	4.9k
Scott J. Cotler United States	40	3.0k 1.0×	3.0k 1.2×	744 0.8×	172 0.3×	232 0.5×	185	4.8k
Jee‐Fu Huang Taiwan	38	3.9k 1.3×	4.0k 1.5×	432 0.4×	211 0.3×	291 0.6×	290	5.4k
Gary P. Jeffrey Australia	32	2.3k 0.8×	2.5k 1.0×	638 0.7×	212 0.3×	237 0.5×	138	4.5k

Countries citing papers authored by David E. Kaplan

Since Specialization

Citations

This map shows the geographic impact of David E. Kaplan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David E. Kaplan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David E. Kaplan more than expected).

Fields of papers citing papers by David E. Kaplan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David E. Kaplan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David E. Kaplan. The network helps show where David E. Kaplan may publish in the future.

Co-authorship network of co-authors of David E. Kaplan

This figure shows the co-authorship network connecting the top 25 collaborators of David E. Kaplan. A scholar is included among the top collaborators of David E. Kaplan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David E. Kaplan. David E. Kaplan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kim, Nicole J., Muyi Li, Philip Vutien, et al.. (2025). Changes in Liver Disease Etiology Support a Lower Alpha-Fetoprotein Threshold for Hepatocellular Carcinoma Screening. Gastroenterology. 170(3). 606–618. 1 indexed citations

John, Binu V., Dustin Bastaich, Catherine Mezzacappa, et al.. (2025). Identifying Metabolic Dysfunction-Associated Steatotic Liver Disease Using Natural Language Processing in a US National Cohort. The American Journal of Gastroenterology. 120(11). 2583–2591. 2 indexed citations

Kaplan, David E., Fan Mu, Sairy Hernandez, et al.. (2024). Overall Survival in Real-World Patients with Unresectable Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab Versus Sorafenib or Lenvatinib as First-Line Therapy: Findings from the National Veterans Health Administration Database. Cancers. 16(20). 3508–3508. 1 indexed citations

Vutien, Philip, Nicole J. Kim, Andrew M. Moon, et al.. (2024). Validation and expansion of Baveno VII criteria for cACLD and CSPH based on liver stiffness and platelet count: Correlation with risk of hepatic decompensation and death. Hepatology. 82(2). 422–437. 4 indexed citations

Serper, Marina, et al.. (2024). Albumin for Spontaneous Bacterial Peritonitis: Care Variation, Disparities, and Outcomes. The American Journal of Gastroenterology. 120(9). 2059–2071. 2 indexed citations

Thompson, Rachel, Tamar H. Taddei, David E. Kaplan, & Anahita Rabiee. (2024). Safety of naltrexone in patients with cirrhosis. JHEP Reports. 6(7). 101095–101095. 11 indexed citations

Tang, Helen, David E. Kaplan, & Nadim Mahmud. (2024). The Impact of Weight Loss Programs on Body Mass Index Trajectory in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Veterans Health Administration Study. The American Journal of Gastroenterology. 119(6). 1192–1196. 1 indexed citations

Tischfield, David J., Alexey Gurevich, Omar Johnson, et al.. (2022). Transarterial Embolization Modulates the Immune Response within Target and Nontarget Hepatocellular Carcinomas in a Rat Model. Radiology. 303(1). 215–225. 44 indexed citations

Mahmud, Nadim, et al.. (2022). Performance of risk prediction models for post-operative mortality in patients undergoing liver resection. The American Journal of Surgery. 225(1). 198–205. 9 indexed citations

10.

John, Binu V., Raphaella Ferreira, David E. Kaplan, et al.. (2022). Third dose of COVID-19 mRNA vaccine appears to overcome vaccine hyporesponsiveness in patients with cirrhosis. Journal of Hepatology. 77(5). 1349–1358. 18 indexed citations

11.

John, Binu V., A. Sidney Barritt, Andrew M. Moon, et al.. (2022). Effectiveness of COVID-19 Viral Vector Ad.26.COV2.S Vaccine and Comparison with mRNA Vaccines in Cirrhosis. Clinical Gastroenterology and Hepatology. 20(10). 2405–2408.e3. 6 indexed citations

12.

Mahmud, Nadim, et al.. (2022). Statin exposure is associated with reduced development of acute-on-chronic liver failure in a Veterans Affairs cohort. Journal of Hepatology. 76(5). 1100–1108. 26 indexed citations

13.

Allara, Elias, Tadaaki Arizumi, Dominik Bettinger, et al.. (2020). Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study. British Journal of Cancer. 124(2). 407–413. 17 indexed citations

14.

Kaplan, David E.. (2020). Hepatitis C Virus. Annals of Internal Medicine. 173(5). ITC33–ITC48. 13 indexed citations

15.

Mahmud, Nadim, et al.. (2019). Survival Benefit of Liver Transplantation for Hepatocellular Carcinoma. Transplantation. 104(1). 104–112. 16 indexed citations

16.

Mahmud, Nadim, David E. Kaplan, Tamar H. Taddei, & David S. Goldberg. (2019). Incidence and Mortality of Acute‐on‐Chronic Liver Failure Using Two Definitions in Patients with Compensated Cirrhosis. Hepatology. 69(5). 2150–2163. 123 indexed citations

17.

Kaplan, David E., Feng Dai, Ayse Aytaman, et al.. (2015). Development and Performance of an Algorithm to Estimate the Child-Turcotte-Pugh Score From a National Electronic Healthcare Database. Clinical Gastroenterology and Hepatology. 13(13). 2333–2341.e6. 112 indexed citations

18.

Harris, Rebecca A., Kazushi Sugimoto, David E. Kaplan, et al.. (2008). Human leukocyte antigen class II associations with hepatitis C virus clearance and virus‐specific CD4 T cell response among Caucasians and African Americans†. Hepatology. 48(1). 70–79. 50 indexed citations

19.

Kaplan, David E., Kazushi Sugimoto, Fusao Ikeda, et al.. (2005). T‐cell response relative to genotype and ethnicity during antiviral therapy for chronic hepatitis C†. Hepatology. 41(6). 1365–1375. 42 indexed citations

20.

Kaplan, David E.. (1993). Unregulated Disposal of Asbestos Contaminated Shower Water Effluent: A Question of Public Health Risk. Journal of environmental health. 55(6). 6. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact